Adherium, established in 2001, is an global respiratory digital health company focusing in patient adherence, remote monitoring, and data management solutions for asthma and COPD patients, clinicians and providers.

The rebrand was strategically timed before their successful IPO on the Australian Securities Exchange (ASX) in 2015, marking a significant milestone in the company’s growth.

Since then, Adherium has expanded its global footprint, establishing offices across New Zealand, Australia, the United Kingdom, and the United States, solidifying its position as a key player in digital health innovation.